Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma

Trial Profile

Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2016

At a glance

  • Drugs Alpelisib (Primary) ; Sotrastaurin (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 28 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top